Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background Technosphere inhaled insulin is a non-invasive alternative to subcutaneous injectable insulin for adults with type 1 or 2 diabetes. In this systematic review and meta-analysis of randomised controlled trials, we aimed to establish the efficacy, safety, and patient acceptability of Technosphere inhaled insulin in patients with diabetes.Methods We searched MEDLINE, the Cochrane Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and relevant US regulatory documents for reports of randomised trials published in English up to May 30, 2015, that compared mealtime Technosphere inhaled insulin with placebo, subcutaneous insulin, or oral antidiabetic drugs in people with type 1 or type 2 diabetes. Two reviewers independently extracted data for outcomes of interest and risk of bias. Endpoints included changes in HbA1c concentration and bodyweight, and safety outcomes, including severe hypoglycaemia and pulmonary toxicity. When three or more studies provided relevant data, we did a meta-analysis for the outcome using a profile-likelihood random-effects model.Findings 13 trials met the inclusion criteria for qualitative systematic review; 12 met the inclusion criteria for quantitative meta-analysis (n=5273; age range 18-80). HbA1c decrease from baseline was greater with subcutaneous insulin than with Technosphere inhaled insulin (net difference 0·16%, 95% CI 0·06-0·25; eight trials). However, inhaled insulin was associated with less weight gain (net difference -1·1 kg, -2·1 to -1·6; three trials) and a smaller risk of severe hypoglycaemia (odds ratio 0·61, 95% CI 0·35-0·92; five trials). Incidence of mild transient cough was increased in people allocated to inhaled insulin (odds ratio 7·82, 6·14-10·15; seven trials) compared with those allocated to active comparator groups, as was the decrease in forced expiratory volume in 1 s (net difference -0·038 L, -0·049 to -0·026; five trials). Quality of life and overall patient satisfaction did not differ significantly between inhaled insulin groups and active comparator groups (no numerical estimate).Interpretation Glycaemic efficacy of Technosphere inhaled insulin is lower than that of subcutaneous insulin, but inhaled insulin has a lower risk of severe hypoglycaemia and weight gain. Long-term outcomes and safety with Technosphere insulin should be further investigated. Until further data for safety become available, Technosphere inhaled insulin should be reserved for healthy adults with diabetes who do not have pulmonary disease and who would otherwise delay initiating or intensifying insulin therapy because they are unwilling or unable to use injectable insulin.Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the BIAsp 30 preparation (premixed insulin analogue containing 30% soluble, rapid-acting insulin aspart and 70% intermediate-acting protamine-bound aspart in each injection), for higher A1C levels, a third injection prior to lunch may be preferable.1084”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1084]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s106 · Cited by 988
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Goldstein, D. E., Little, R. R., Lorenz, R. A., Malone, J. I., Nathan, D., Peterson, C. M., & Sacks, D. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1761 · Cited by 625
Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010
Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2411 · Cited by 532
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
Hardy, R., & Thompson, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6<671::aid-sim205>3.0.co;2-5 · Cited by 527
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
HARDY, R. J., & THOMPSON, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6<619::aid-sim188>3.0.co;2-a · Cited by 522
Research works printed but not linked: 1
- Petrucci, 2009, Pulmonary function tests remain similar in patients who received Technosphere insulin and in patients currently receiving standard anti-diabetic therapy, Diabetologia, 52, S361
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
The Discovery of Insulin: An Important Milestone in the History of Medicine
Vecchio, I., Tornali, C., Bragazzi, N. L., & Martini, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00613 · Cited by 272
Recent Advances in Insulin Therapy
Wilson, L. M., & Castle, J. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0065 · Cited by 64
Insulin Therapy in Type 2 Diabetes
Aschner, P. J. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001088 · Cited by 56
Advances in Audio-Based Systems to Monitor Patient Adherence and Inhaler Drug Delivery
Taylor, T. E., Zigel, Y., Looze, C. D., Sulaiman, I., Costello, R. W., & Reilly, R. B. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.08.1162 · Cited by 46
Metadata
- Authors
- Pittas, A. G., Westcott, G. P., & Balk, E. M.
- Affiliations
- Tufts Medical Center (US)
- Brown University (US)
- Corresponding author
- Pittas, Anastassios G
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 3
- Issue
- 11
- Pages
- 886-894
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2127114165
- Cited by
- 47
- References
- 25
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 2
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- technosphere, inhaled insulin, type 1 diabetes, type 2 diabetes, glycemic control, HbA1c, weight gain, hypoglycemia, pulmonary toxicity, cough, forced expiratory volume, patient acceptability, oral antidiabetic drugs, quality of life, patient satisfaction, adverse events
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Registries, Technology, Pharmaceutical, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult, Dry Powder Inhalers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/s2213-8587(15)00280-6
- The paper
- Pittas, A. G., Westcott, G. P., & Balk, E. M. (2015). Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(15)00280-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.